Opinion: Writer sees biotechs entering 2005 with "good momentum"

12/30/2004 | TheStreet.com

Although 2004 is replete with "blowups" of biotechnology companies, the sector is entering 2005 with good momentum, the most heavily capitalized staying stronger than small-cap firms, according to a senior writer at TheStreet.com. U.S. cutbacks in Medicare reimbursements next year could lead to a trend change in drug usage and affect biotech companies such as Amgen, Genentech and Biogen Idec.

View Full Article in:

TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD